Tridente, G., <br/><br/>
Adverse events and oncotargeted kinase inhibitors / 
Giuseppe Tridente. 
 - London :  Academic Press,  ©2017. 
 - xix, 715 p. ;  28 cm 
<br/><br/>Includes bibliographical references and index. 
<br/><br/>Introduction -- Kinases -- Kinase inhibitors -- Adverse events -- Imantinib -- Gefitinib -- Erlotinib -- Sorafenib -- Sunitinib -- Dasatinib -- Lapatinib -- Nilotinib -- Pazopanib -- Vandetanib -- Vemurafenib -- Crizotinib -- Ruxolitinib -- Axitinib -- Bosutinib -- Regorafenib -- Cabozantinib -- Ponatinib -- Dabrafenib -- Trametinib -- Afatinib -- Idelaisib -- Ibrutinib -- Overview -- Conclusion and perspectives. 
<br/><br/><label>ISBN: </label>9780128094006 (hbk.) 0128094001 (hbk.) 
<br/><br/><label>LCCN: </label>2017302047 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Protein-tyrosine kinase--Inhibitors.<br/>Protein-tyrosine kinase $x Inhibitors.<br/>Protein-tyrosine kinase--Inhibitors.
<br/><br/><label>LC Class. No.: </label>RC271.P76  / T75 2017 
<br/><br/><label>Dewey Class. No.: </label>615.7/98